End-of-day quote
Other stock markets
|
||
- | - |
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Sales 2024 * | 120B 86.88M 0 7.24B | Sales 2025 * | 145B 105M 0 8.75B | Capitalization | 230B 166M 0 13.88B |
---|---|---|---|---|---|
Net income 2024 * | 23B 16.65M - 1.39B | Net income 2025 * | 30B 21.72M - 1.81B | EV / Sales 2024 * | 0.85 x |
Net cash position 2024 * | 128B 92.96M 0 7.75B | Net cash position 2025 * | 152B 110M 0 9.2B | EV / Sales 2025 * | 0.53 x |
P/E ratio 2024 * |
10.6
x | P/E ratio 2025 * |
8.06
x | Employees | - |
Yield 2024 * |
2.54% | Yield 2025 * |
2.54% | Free-Float | 56.96% |
Managers | Title | Age | Since |
---|---|---|---|
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Woo-Jae Lim
BRD | Director/Board Member | 46 | 25/21/25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Dong-Jin Choi
BRD | Director/Board Member | 64 | 21/19/21 |
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
-7.81% | 235B | |
0.00% | 19.58B | |
+11.57% | 18.85B | |
+8.42% | 11.4B | |
-19.32% | 8.65B | |
+15.38% | 7.45B | |
+11.66% | 6.03B | |
-8.64% | 3.87B | |
-19.43% | 3.72B |